Brief: Calliditas Therapeutics Receives Positive CHMP Opinion In IgA Nephropathy
19/05/2022 13:36
May 19 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* RECEIVES POSITIVE CHMP OPINION IN IGA NEPHROPATHY
* IF CONFIRMED BY EUROPEAN COMMISSION (EC), KINPEYGO WILL BE
FIRST
AND ONLY APPROVED TREATMENT FOR IGAN, DISEASE OF KIDNEY
* UPON APPROVAL KINPEYGO, WHICH WAS DEVELOPED UNDER NAME
NEFECON,
WILL BE MARKETED EXCLUSIVELY BY STADA ARZNEIMITTEL AG.
Source text for Eikon: ID:nWkr9rvm0t
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations